Evidence assessments and guideline recommendations in Lyme disease: The clinical management of known tick bites, erythema migrans rashes and persistent disease

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 9, 2014, Pages 1103-1135

  Cameron, Daniel J ^a   Johnson, Lorraine B ^b   Maloney, Elizabeth L ^c  

^a International Lyme and Associates Diseases Society   (United States)

^b LymeDiseaseorg   (United States)

^c Partnership for Healing and Health Ltd   (United States)

Author keywords

antibiotic prophylaxis; antibiotics; erythema migrans; GRADE; Lyme disease; persistent disease; treatment

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFUROXIME; DOXYCYCLINE; PENICILLIN V;

ADVERSE OUTCOME; ANTIBIOTIC PROPHYLAXIS; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ERYTHEMA CHRONICUM MIGRANS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; LYME DISEASE; MEDICAL DECISION MAKING; NONHUMAN; PATIENT PREFERENCE; PERSISTENT INFECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; RETREATMENT; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TICK BITE; TREATMENT DURATION; TREATMENT PLANNING; ANTIBIOTIC RESISTANCE; BORRELIA BURGDORFERI; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GLOSSITIS, BENIGN MIGRATORY; MICROBIOLOGY; PROCEDURES; TICK BITES;

ANTIBIOTIC PROPHYLAXIS; BORRELIA BURGDORFERI; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; EVIDENCE-BASED MEDICINE; GLOSSITIS, BENIGN MIGRATORY; HUMANS; LYME DISEASE; PRACTICE GUIDELINES AS TOPIC; TICK BITES;

EID: 84905836832     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.940900     Document Type: Review

References (213)

1. Sackett D, Straus S, Richardson W, et al. Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone; Edinburgh, London: 2000
2. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129(1):174-81
3. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454): 1490
4. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Cmaj 2003; 169(7):677-80
5. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650): 924-6
6. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines Rating the quality of evidence. J Clin Epidemiol 2011; 64(4):401-6
7. Hayes E. Lyme disease. Clin Evid 2003(10): 887-99
8. Scott IA, Guyatt GH. Suggestions for improving guideline utility and trustworthiness. Evid Based Med 2013;19: 41-6
9. Classifying recommendations for clinical practice guidelines. Pediatrics 2004;114(3): 874-7
10. Living well with chronic illness: A call for public health action. Available from: www.iom.edu/Reports/2012/Living-Well-with-Chronic-Illness.aspx [Last accessed 1 March 2014]
11. Institute of Medicine (Committee on Quality of Health Care in America). Crossing the quality chasm: A new health system for the 21st century. National Academies Press; Washington, DC, USA: 2001. p. 360
12. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336(7652):1049-51
13. What is shared decision making? Available from: www. informedmedicaldecisions.org/what-is-shared-decision-making/[Last accessed 1 March 2014]
14. FDA. Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. Available from: www.google.com/url?sa=t&rct=j&q=&esrc=s&source= web&cd=1&cad=rja& uact=8&ved=0CCgQFjAA&url=http%3A%2F%2F www.fda. gov%2Fdownloads%2FMedicalDevices%2FDeviceRegulationandGuidance%2FGuidanceDocume nts%2FUCM296379. pdf&ei=hCY4U-mGLoSYrAeGz4DYAQ& usg= AFQjCNFD3hnFwqaq990lfPMUWg 4dD22TYA&sig2=Ihrt0xGS-c-764Rqe41Vqg&bvm=bv. 63808443,d.bmk [Last accessed 1 March 2014]
15. Zhang X, Meltzer MI, Pena CA, et al. Economic impact of Lyme disease. Emerg Infect Dis 2006;12(4):653-60
16. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008;70(13): 992-1003
17. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. Neurology 2003;60(12): 1923-30
18. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345(2):85-92
19. Clinical Practice Guidelines we can trust. Available from: www.nap.edu/catalog.php? recordid=13058 [Last accessed 1 March 2014]
20. Institute of Medicine (US) Committee on Lyme Disease and Other Tick-Borne Diseases: The State of the Science. In: Critical needs and gaps in understanding prevention, amelioration, and resolution of lyme and other tick-borne diseases: the short-term and long-term outcomes: workshop report. National Academies Press; Washington, DC, USA: 2011
21. Corapi KM, White MI, Phillips CB, et al. Strategies for primary and secondary prevention of Lyme disease. Nat Clin Pract Rheumatol 2007;3(1):20-5
22. Clark RP, Hu LT. Prevention of lyme disease and other tick-borne infections. Infect Dis Clin North Am 2008;22(3): 381-96; vii
23. Reported cases of Lyme disease by year, United States, 1995-2009. Available from: www.cdc.gov/lyme/stats/chartstables/casesbyyear.html [Last accessed 1 March 2014]
24. Vazquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics 2003;112(2):e93-7
25. Seltzer EG, Gerber MA, Cartter ML, et al. Long-term outcomes of persons with Lyme disease. JAMA 2000;283(5):609-16
26. Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics 1998; 102(4 Pt 1):905-8
27. Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med 1994;121(8):560-7
28. Skogman BH, Glimaker K, Nordwall M, et al. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics 2012;130(2):262-9
29. Eikeland R, Mygland A, Herlofson K, Ljostad U. European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand 2011;124(5):349-54
30. Asch ES, Bujak DI, Weiss M, et al. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 1994;21(3):454-61
31. Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999;5(3): 321-8
32. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990;323(21): 1438-44
33. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999;180(2):377-83
34. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: A meta-analysis of reported symptoms. Int J Epidemiol 2005;34(6): 1340-5
35. Jones KD, Burckhardt CS, Deodhar AA, et al. A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum 2008;58(2):612-22
36. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes 2011; 9(1):71
37. Tang S, Calkins H, Petri M. Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. Rheumatology 2004;43(5):609-14
38. Ware JE, Kosinski M. SF-36 physical & mental health summary scores: A manual for users of version 1. 2nd edition; 1994. p. 1-238
39. Calandre EP, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: A two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord 2011;12:95
40. Burckhardt CS, Jones KD. Effects of chronic widespread pain on the health status and quality of life of women after breast cancer surgery. Health Qual Life Outcomes 2005;3:30
41. Oksi J, Nikoskelainen J, Hiekkanen H, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: A double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis 2007;26(8):571-81
42. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur J Clin Microbiol Infect Dis 1998;17(10):715-19
43. Liegner KB, Shapiro JR, Ramsay D, et al. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting Borrelia burgdorferi infection. J Am Acad Dermatol 1993;28(2 Pt 2):312-14
44. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15(6):274-80
45. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105(7):1636-41
46. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother 1992;30(4):543-50
47. Strle F, Preac-Mursic V, Cimperman J, et al. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 1993; 21(2):83-8
48. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993;21(6):367-72
49. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000;28(3):153-6
50. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99(1):22-6
51. Berger BW. Treatment of erythema chronicum migrans of Lyme disease. Ann N Y Acad Sci 1988;539:346-51
52. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995;39(3):661-7
53. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med 1992;92(4):396-403
54. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis-randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1(8596):1191-4
55. Cameron DJ. Consequences of treatment delay in Lyme disease. J Eval Clin Pract 2007;13(3):470-2
56. Costello CM, Steere AC, Pinkerton RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. J Infect Dis 1989;159(1):136-9
57. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child 1993;147(9):945-7
58. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992;327(25):1769-73
59. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345(2):79-84
60. Warshafsky S, Lee DH, Francois LK, et al. Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. J Antimicrob Chemother 2010;65(6):1137-44
61. Warshafsky S, Nowakowski J, Nadelman RB, et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996;11(6):329-33
62. Maloney EL. The management of Ixodes scapularis bites in the upper Midwest. WMJ:2011;110(2):78-81.quiz 85
63. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease-United States, 1992-2006. MMWR Surveill Summ 2008; 57(10):1-9
64. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983;99(1): 76-82
65. Duray PH. Clinical pathologic correlations of Lyme disease. Rev Infect Dis 1989; 11(Suppl 6):S1487-93
66. Coyle PK, Schutzer SE. Neurologic presentations in Lyme disease. Hosp Pract (Off Ed) 1991;26(11):55-66.discussion 66, 69-70
67. Lo R, Menzies DJ, Archer H, Cohen TJ. Complete heart block due to Lyme carditis. J Invasive Cardiol 2003;15(6):367-9
68. Albert S, Schulze J, Riegel H, Brade V. Lyme arthritis in a 12-year-old patient after a latency period of 5 years. Infection 1999; 27(4-5):286-8
69. Zeidner NS, Brandt KS, Dadey E, et al. Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. Antimicrob Agents Chemother 2004;48(7): 2697-9
70. Zeidner NS, Massung RF, Dolan MC, et al. A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite. J Med Microbiol 2008;57(Pt 4):463-8
71. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43(9):1089-134
72. Lee J, Wormser GP. Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. Int J Antimicrob Agents 2008;31(3):235-9
73. Volkman D. Chemoprophylaxis against Lyme disease. Lancet Infect Dis 2008;8(3): 145; author reply 146-147
74. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996;124(9):785-91
75. Lawrence C, Lipton RB, Lowy FD, Coyle PK. Seronegative chronic relapsing neuroborreliosis. Eur Neurol 1995;35(2): 113-17
76. Embers ME, Barthold SW, Borda JT, et al. Persistence of Borrelia burgdorferi in Rhesus Macaques following antibiotic treatment of disseminated infection. PLoS One 2012; 7(1):e29914
77. Thompson GR 3rd, Lunetta JM, Johnson SM, et al. Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis. Clin Infect Dis 2011;53(6):e20-4
78. Talwar S, Tutakne MA, Tiwari VD. VDRL titres in early syphilis before and after treatment. Genitourin Med 1992;68(2): 120-2
79. Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africä Circulation 2009;120(8): 709-13
80. Dattwyler RJ, Volkman DJ, Luft BJ, et al. Seronegative Lyme disease. Dissociation of specific T-and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med 1988; 319(22):1441-6
81. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, et al. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996;34(1):1-9
82. Weder B, Wiedersheim P, Matter L, et al. Chronic progressive neurological involvement in Borrelia burgdorferi infection. J Neurol 1987;234(1):40-3
83. Aucott J, Morrison C, Munoz B, et al. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis 2009;9:79
84. Berger BW. Dermatologic manifestations of Lyme disease. Rev Infect Dis 1989; 11(Suppl 6):S1475-81
85. Piesman J, Hojgaard A. Protective value of prophylactic antibiotic treatment of tick bite for Lyme disease prevention: an animal model. Ticks Tick Borne Dis 2012;3(3): 193-6
86. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999;28(3): 569-74
87. Cameron D. Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. Minerva Med 2008;99(5):489-96
88. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117(4): 273-80
89. Borg R, Dotevall L, Hagberg L, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 2005; 37(6-7):449-54
90. Frank C, Fix AD, Pena CA, Strickland GT. Mapping Lyme disease incidence for diagnostic and preventive decisions, Maryland. Emerg Infect Dis 2002;8(4): 427-9
91. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002;109(6):1173-7
92. Cerar D, Cerar T, Ruzic-Sabljic E, et al. Subjective symptoms after treatment of early Lyme disease. Am J Med 2010;123(1): 79-86
93. Thaisetthawatkul P, Logigian EL. Peripheral nervous system manifestations of lyme borreliosis. J Clin Neuromuscul Dis 2002; 3(4):165-71
94. Altman DG. Missing outcomes in randomized trials: addressing the dilemma. Open Med 2009;3(2):e51-3
95. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Wiley-Interscience; Hoboken, NJ, USA: 2004
96. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4
97. Carneiro AV. Estimating sample size in clinical studies: basic methodological principles. Rev Port Cardiol 2003;22(12): 1513-21
98. Chu R, Walter SD, Guyatt G, et al. Assessment and implication of prognostic imbalance in randomized controlled trials with a binary outcome-A simulation study. PLoS One 2012;7(5):e36677
99. Tarnow-Mordi WO. What have we learned about randomized, controlled trials in neonatal sepsis? Pediatr Crit Care Med 2005;6(3 Suppl):S146-9
100. Strle F, Maraspin V, Lotric-Furlan S, et al. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 1996;24(1):64-8
101. Maraspin V, Lotric-Furlan S, Cimperman J, et al. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr 1999;111(22-23):923-32
102. Stanek G, Reiter M. The expanding Lyme Borrelia complex-clinical significance of genomic species? Clin Microbiol Infect 2011;17(4):487-93
103. Logar M, Ruzic-Sabljic E, Maraspin V, et al. Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Infection 2004;32(1):15-19
104. Strle F, Nadelman RB, Cimperman J, et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999;130(1):32-6
105. Cooper C. Safety of long-term therapy with penicillin and penicillin derivatives. Center for Drug Evaluation and Research. Available from: www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ ucm072755.htm [Last accessed 3 January 2014]
106. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther 2005;27(9):1329-42
107. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998;20(5): 993-1008. Discussion 1992
108. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013;7(2):e56-67
109. Donta ST. Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 1997; 25(Suppl 1):S52-6
110. Donta ST. Macrolide therapy of chronic Lyme disease. Med Sci Monit 2003;9(11): PI136-42
111. Cimmino MA, Moggiana GL, Parisi M, Accardo S. Treatment of Lyme arthritis. Infection 1996;24(1):91-3
112. Dattwyler RJ, Halperin JJ, Pass H, Luft BJ. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis 1987;155(6): 1322-5
113. Pfister HW, Preac-Mursic V, Wilske B, et al. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991;163(2):311-18
114. Steere AC, Green J, Schoen RT, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985;312(14):869-74
115. Hunfeld KP, Weigand J, Wichelhaus TA, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents 2001;17(3):203-8
116. Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from ixodes ticks. Clin Microbiol Rev 2006; 19(4):708-27
117. Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275(21):1657-60
118. Sperling J, Middelveen M, Klein D, Sperling F. Evolving perspectives on Lyme borreliosis in Canada. Open Neurol J 2013;6:94-103
119. Johnson L, Wilcox S, Mankoff J, Stricker RB. Severity of chronic Lyme disease compared to other chronic conditions: A quality of life survey. Peer J 2014;2:e322
120. Donta ST. Issues in the diagnosis and treatment of lyme disease. Open Neurol J 2012;6:140-5
121. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? Qual Life Res 2013;22(1):75-84
122. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138(9):697-704
123. Piesman J, Dolan MC, Happ CM, et al. Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice. Infect Immun 1997; 65(10):4043-7
124. Nadelman RB, Hanincova K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012;367(20):1883-90
125. Sjowall J, Ledel A, Ernerudh J, et al. Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: A randomized, prospective, cross-over study. BMC Infect Dis 2012;12:186
126. Delong AK, Blossom B, Maloney EL, Phillips SE. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: A biostatistical review of randomized, placebo-controlled, clinical trials. Contemp Clin Trials 2012;33(6):1132-42
127. Fallon BA, Petkova E, Keilp JG, Britton CB. A reappraisal of the U.S. clinical trials of post-treatment Lyme disease syndrome. Open Neurol J 2012;6:79-87
128. Pollina DA, Sliwinski M, Squires NK, Krupp LB. Cognitive processing speed in Lyme disease. Neuropsychiatry Neuropsychol Behav Neurol 1999;12(1): 72-8
129. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010;37(3):534-41
130. Stricker RB, Johnson L. Lyme disease: A turning point. Expert Rev Anti Infect Ther 2007;5(5):759-62
131. Stricker RB, Green CL, Savely VR, et al. Safety of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. Minerva Med 2010;101(1): 1-7
132. Haupl T, Hahn G, Rittig M, et al. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum 1993;36(11):1621-6
133. Schmidli J, Hunziker T, Moesli P, Schaad UB. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis 1988;158(4):905-6
134. Preac-Mursic V, Pfister HW, Spiegel H, et al. First isolation of Borrelia burgdorferi from an iris biopsy. J Clin Neuroophthalmol 1993;13(3):155-61. discussion 162
135. Preac-Mursic V, Weber K, Pfister HW, et al. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 1989;17(6):355-9
136. Bradley JF, Johnson RC, Goodman JL. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Intern Med 1994;120(6):487-9
137. Marques A, Telford SR 3rd, Turk SP, et al. Xenodiagnosis to detect Borrelia burgdorferi infection: A first-in-human study. Clin Infect Dis 2014;58(7):937-45
138. Hodzic E, Feng S, Holden K, et al. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 2008;52(5):1728-36
139. Barthold SW, Hodzic E, Imai DM, et al. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother 2010;54(2):643-51
140. Johnson L, Aylward A, Stricker RB. Healthcare access and burden of care for patients with Lyme disease: A large United States survey. Health Policy 2011;102(1): 64-71
141. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: A systematic review of 200 published prospective studies. Mayo Clin Proc 2006;81(9):1159-71
142. FDA Drug Bulletin. Use of approved drugs for unlabeled indications. FDA Drug Bulletin 1982; 12(1):4-5. Available from: www.circare.org/fda/ fdadrugbulletin-041982.pdf [Last accessed 3 January 14]
143. Fugh-Berman A, Melnick D. Off-label promotion, on-target sales. PLoS Med 2008;5(10):e210
144. Snyder L, Leffler C. Ethics manual: fifth edition. Ann Intern Med 2005;142(7): 560-82
145. Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994;330(4):229-34
146. Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med 1999;31(3):225-32
147. Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect 2004;6(3):312-18
148. Cabello FC, Godfrey HP, Newman SA. Hidden in plain sight: borrelia burgdorferi and the extracellular matrix. Trends Microbiol 2007;15(8):350-4
149. Szczepanski A, Benach JL. Lyme borreliosis: host responses to Borrelia burgdorferi. Microbiol Rev 1991;55(1):21-34
150. Hodzic E, Feng S, Freet KJ, Barthold SW. Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect Immun 2003; 71(9):5042-55
151. Mahmoud AA. The challenge of intracellular pathogens. N Engl J Med 1992;326(11):761-2
152. Brouqui P, Badiaga S, Raoult D. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob Agents Chemother 1996;40(6):1552-4
153. Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 1993;167(5): 1074-81
154. Livengood JA, Gilmore RD Jr. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect 2006;8(14-15):2832-40
155. Sapi E, Bastian SL, Mpoy CM, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS One 2012;7(10):e48277
156. Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997;89(2):275-85
157. Coutte L, Botkin DJ, Gao L, Norris SJ. Detailed analysis of sequence changes occurring during VlsE antigenic variation in the mouse model of Borrelia burgdorferi infection. PLoS Pathog 2009;5(2):e1000293
158. Liang FT, Jacobs MB, Bowers LC, Philipp MT. An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J Exp Med 2002;195(4): 415-22
159. Barbour AG, Restrepo BI. Antigenic variation in vector-borne pathogens. Emerg Infect Dis 2000;6(5):449-57
160. Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J Clin Microbiol 2000; 38(1):382-8
161. Mursic VP, Wanner G, Reinhardt S, et al. Formation and cultivation of Borrelia burgdorferi spheroplast-L-form variants. Infection 1996;24(3):218-26
162. Al-Robaiy S, Dihazi H, Kacza J, et al. Metamorphosis of Borrelia burgdorferi organisms-RNA, lipid and protein composition in context with the spirochetes' shape. J Basic Microbiol 2010;50(Suppl 1): S5-17
163. Duray PH, Yin SR, Ito Y, et al. Invasion of human tissue ex vivo by Borrelia burgdorferi. J Infect Dis 2005;191(10): 1747-54
164. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother 1995;39(5):1127-33
165. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 2000;146(Pt 1): 119-27
166. Brorson O, Brorson SH. In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection 1998;26(3):144-50
167. Kraiczy P, Hellwage J, Skerka C, et al. Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem 2004;279(4):2421-9
168. Pausa M, Pellis V, Cinco M, et al. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. J Immunol 2003;170(6):3214-22
169. Kraiczy P, Skerka C, Kirschfink M, et al. Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody. Int J Med Microbiol 2002;291(Suppl 33):141-6
170. Hartiala P, Hytonen J, Suhonen J, et al. Borrelia burgdorferi inhibits human neutrophil functions. Microbes Infect 2008; 10(1):60-8
171. Hartiala P, Hytonen J, Pelkonen J, et al. Transcriptional response of human dendritic cells to Borrelia garinii-defective CD38 and CCR7 expression detected. J Leukoc Biol 2007;82(1):33-43
172. Lazarus JJ, Kay MA, McCarter AL, Wooten RM. Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages. Infect Immun 2008;76(3): 1153-62
173. Giambartolomei GH, Dennis VA, Philipp MT. Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys. Infect Immun 1998;66(6):2691-7
174. Sartakova ML, Dobrikova EY, Terekhova DA, et al. Novel antibiotic-resistance markers in pGK12-derived vectors for Borrelia burgdorferi. Gene 2003;303:131-7
175. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with lyme disease. Clin Infect Dis 2007;45(2):149-57
176. Auwaerter PG. Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to lyme disease. Clin Infect Dis 2007;45(2):143-8
177. Cimmino MA, Accardo S. Long term treatment of chronic Lyme arthritis with benzathine penicillin. Ann Rheum Dis 1992;51(8):1007-8
178. Mullegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children-A prospective study. Infection 1991;19(4):279-83
179. Alder J, Mitten M, Jarvis K, et al. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother 1993;37(6): 1329-33
180. Cunha BA. Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 2000;30(1):237-8
181. Kraiczy P, Weigand J, Wichelhaus TA, et al. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 2001;45(9): 2486-94
182. Nowakowski J, McKenna D, Nadelman RB, et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000;9(6): 563-7
183. Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 1990;34(11): 2133-6
184. Rahn DW. Lyme disease: clinical manifestations, diagnosis, and treatment. Semin Arthritis Rheum 1991;20(4):201-18
185. Dattwyler RJ, Volkman DJ, Conaty SM, et al. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990;336(8728): 1404-6
186. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997;337(5):289-94
187. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992;36(8): 1788-90
188. Dever LL, Jorgensen JH, Barbour AG. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: A microdilution MIC method and time-kill studies. J Clin Microbiol 1992;30(10):2692-7
189. Johnson RC. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev Infect Dis 1989;11(Suppl 6):S1505-10
190. Preac-Mursic V, Wilske B, Schierz G, et al. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1989;8(7): 651-3
191. Weber K, Neubert U, Thurmayr R. Antibiotic therapy in early erythema migrans disease and related disorders. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263(3):377-88
192. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: A pilot study. Antimicrob Agents Chemother 1996;40(2):468-9
193. Steere AC, Malawista SE, Newman JH, et al. Antibiotic therapy in Lyme disease. Ann Intern Med 1980;93(1):1-8
194. Robles M, Toscano E, Cotta J, et al. Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. Curr Drug Saf 2010;5(3): 212-22
195. Brorson O, Brorson SH. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole. Int Microbiol 2004;7(2):139-42
196. Brorson O, Brorson SH. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole. APMIS 1999;107(6):566-76
197. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991;34(8): 1056-60
198. Smith BG, Cruz AI Jr, Milewski MD, Shapiro ED. Lyme disease and the orthopaedic implications of Lyme arthritis. J Am Acad Orthop Surg 2011;19(2):91-100
199. Rupprecht TA, Elstner M, Weil S, Pfister HW. Autoimmune-mediated polyneuropathy triggered by borrelial infectioñ Muscle Nerve 2008;37(6):781-5
200. Institute of Medicine. Clinical practice guidelines we can trust. National Academies Press; Washington, DC,USA: 2011
201. Shaneyfelt T. In guidelines we cannot trust: comment on "failure of clinical practice guidelines to meet Institute of Medicine Standards". Arch Intern Med 2012;1-2
202. Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16(4):617-24
203. Lo Coco D, La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol 2012;19(5):760-3
204. Kaminska M, Kimoff R, Benedetti A, et al. Obstructive sleep apnea is associated with fatigue in multiple sclerosis Mult Scler 2012;18(8):1159-69
205. Duncan B, White A, Rahman A. Acupuncture in the treatment of fibromyalgia in tertiary care-A case series. Acupunct Med 2007;25(4):137-47
206. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999; 42(1):76-83
207. Ndao-Brumblay SK, Green CR. Racial differences in the physical and psychosocial health among black and white women with chronic pain. J Natl Med Assoc 2005; 97(10):1369-77
208. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973;9(1):13-28
209. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000:25(24):3130-9
210. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121-3
211. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18(5):728-33
212. Fallon J, Bujak DI, Guardino S, Weinstein A. The Fibromyalgia Impact Questionnaire: A useful tool in evaluating patients with post-Lyme disease syndrome. Arthritis Care Res 1999;12(1):42-7
213. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30(2):191-7